
Three of five patients with breast cancer that had spread to other organs responded to Oncology Ventures’ LiPlaCis or had their disease become stable with it, according to early results of the Phase 2 portion of a Phase 1/2 clinical trial.
Oncology Ventures, a spinoff of Denmark’s Medical Prognosis Institute, is continuing to enroll patients in the trial (NCT01861496). It hopes to recruit 12 to 15 women with advanced breast cancer whose tumors are likely to respond to LiPlaCis, a platinum-based chemotherapy with a unique formulation. That formulation is a capsule that delivers the therapy directly to a tumor.
The Medical Prognosis Institute developed a tool that does a good job of predicting which advanced breast cancer patients are likely to benefit from LiPlaCis.
Source: Breast Cancer News







